Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What potential drug-drug interactions does EMGALITY® (galcanezumab-gnlm) have?

Drug interaction studies were not conducted. No pharmacokinetic drug interactions are expected based on the characteristics of Emgality (galcanezumab).


Drug Interactions with Galcanezumab Are Not Known or Expected

Pharmacokinetic Characteristics of Galcanezumab Metabolism

Galcanezumab is an immunoglobulin G (subclass 4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous immunoglobulin G.1-4

As such, it is not expected to

  • inhibit metabolic or induce enzymatic pathways
  • be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
  • produce any active metabolites.1,2,4,5

Drug Interaction Studies Were Not Conducted

Based on the pharmacokinetic characteristics of galcanezumab, drug interactions are not expected.3 Therefore, no drug interaction studies were conducted.1

There are no known interactions for galcanezumab, drug-drug or otherwise.1


The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780

3Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs - lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180. https://doi.org/10.3390/pharmaceutics12121180

4Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

5Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178

Date of Last Review: January 25, 2022

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical